# IMMUNOGLOBULIN ISOANTIGENS (ALLOTYPES) IN THE MOUSE

## II. Allotypic Analysis of Three $\gamma G_2$-Myeloma Proteins from (NZB × BALB/c)$F_1$ Hybrids and of Normal $\gamma G_2$-Globulins*

By NOEL L. WARNER,‡ Ph.D., LEONARD A. HERZENBERG, Ph.D., and GIDEON GOLDSTEIN,§ M.D.

*(From the Department of Genetics, Stanford University, School of Medicine, Palo Alto, California, and the Clinical Research Unit of the Walter and Eliza Hall Institute of Medical Research, and the Royal Hospital, Melbourne, Australia)*

(Received for publication 22 November 1965)

Genetically controlled isoantigenic differences (allotypes) of 3 of the immunoglobulin classes of mice have recently been demonstrated (1–7). These antigenic polymorphisms provide useful markers in studies of protein synthesis and some aspects of somatic cell genetics (8). Myeloma proteins produced by plasma cell tumors have been particularly useful in defining the structure, subdivisions, and genetic control of immunoglobulin molecules (9–11).

The induction of plasma cell tumors in mice has been reported by several groups (12, 13) using prolonged treatment of mice with mineral oil or other agents. These tumors have usually been produced in BALB/c mice with only the occasional tumor reported in C3H, CBA, DBA/2, or hybrids of these strains (13).

A new series of transplantable plasma cell tumors has recently been developed in hybrid mice of the cross NZB × BALB/c (14). The antigenic classification (as defined by Fahey et al., 15 and 16) of the myeloma proteins of 8 plasma cell tumors produced in these hybrid mice has previously been reported. It was shown that the 8 lines comprised 4 $\gamma$A-, 1 $\gamma G_1$-, 1 $\gamma G_{2b}$-, and 2 $\gamma G_{2a}$-myelomas.

Some human myeloma proteins carry the isoantigens (Gm and InV) (10, 17–19) of normal human immunoglobulins. These proteins carry the Gm type of only one allele even from patients heterozygous at this locus (20–22). In instances where more than one specificity of a Gm allele has been defined, myeloma proteins can carry these several specificities (22–24).

We have undertaken a detailed isoantigenic analysis of the 3 $\gamma G_2$-myelomas produced in (NZB × BALB/c)F hybrid mice, in order to see whether (*a*) the

* This investigation was supported by United States Public Health Service Research Grants GM-12075 and CA-04681 and 5TI-GM295.

‡ Fellow of the Helen Hay Whitney Foundation.

§ Working with the aid of a grant from the National Health and Medical Research Council of Australia.



Downloaded from www.jem.org on May 24, 2005

myeloma protein carries isoantigenic specificities of one or both of the parental strains, and (*b*) it carries all of the isoantigenic specificities normal to its class of immunoglobulin.

## *Materials and Methods*

*Plasma Cell Tumors.*—The origin of the transplantable plasma cell tumors GPC-5, GPC-7, and GPC-8 has been described (14). Each of these plasma cell tumors was produced and passaged in (NZB × BALB/c)[1]$F_1$ hybrid mice. Sera were obtained from the original hosts of GPC-7 and GPC-8 and from a first passage recipient of GPC-5. The serum samples were preserved with 0.1% sodium azide and sent air mail from Melbourne to Palo Alto where they were kept at −20°C until analysis.

Myeloma proteins from previously established lines were isolated for use as standard antigens and inhibitors. Tumors RPC-5, (adj PC-5), MPC-1, MPC-11, MPC-31 were passaged in BALB/c mice; 5563 was passaged in C3H mice (15).

*Nomenclature of Immunoglobulins.*—The nomenclature for immunoglobulin classes proposed (25) by the World Health Organization Committee on nomenclature of human immunoglobulins has been followed. The 5 immunoglobulin classes of mice defined by Fahey et al., (15, 16) are here called $\gamma$M, $\gamma$A, $\gamma G_1$, $\gamma G_{2a}$, $\gamma G_{2b}$. We have changed $7S\gamma_1$ to $\gamma G_1$ etc., in order to more closely follow the World Health Organization Committee recommendation.

An extension of this system for the $\gamma$G-globulins of mice is under consideration and will be followed when adopted. The isoantigenic(allotypic) loci for $\gamma G_{2a}$ and $\gamma$A have previously been named Ig-1 and Ig-2. In this paper Ig-3 is the designation for the allotypes appearing on $\gamma G_{2b}$-molecules. Specificity designation is made following the proposal of Snell et al. (26) for the H-2 locus; e.g., for C3H $\gamma G_{2a}$-isoantigenic specificities, Ig-1. 1, 2, 6, 7, 8, 9, 10.

*Isolation of Myeloma Proteins*—. Zone agar gel electrophoresis of 50 $\mu$l samples of sera from GPC-5, GPC-7, and GPC-8 was performed in 1% Ionagar (Oxoid Division, Consolidated Laboratories, Chicago Heights, Illinois) in veronal buffer pH 8.2 on glass plates at 6 to 8 v/cm, 30 ma for 40 to 60 min. Serial 5 mm strips were then cut perpendicular to the direction of current flow and protein was extruded from these strips by centrifugation at 100,000 × *g* for 1 hr. Protein determinations on the extruded fractions revealed a typical myeloma spike in the slow cathodal region. Portions of the fractions containing these myeloma spikes were then iodinated or used as inhibitors. The contamination of these 3 fractions with normal gamma globulins is about 5% (as determined by inhibition assays for isoantigens not carried on the myeloma protein).

*Isoantigenic Analysis.*—Precipitation of iodinated antigens, inhibition of precipitation of iodinated antigens, and the production of antiallotype sera, have been previously described (6). Briefly, the slow gamma globulins from a normal or myeloma-containing serum are purified by ammonium sulphate precipitation, zone electrophoresis, and Sephadex gel filtration, and then conjugated with $I^{125}$- by the chloramine-T method. Fifty $\mu$l portions of appropriate dilutions of a labeled antigen in 3% BSA in 0.05 M tris buffer, pH 7.6 are pipetted into 6 × 50 mm tubes. To each of these is added 5 $\mu$l of a dilution of either a purified protein antigen (the standard of known protein concentration) or a dilution of serum from normal or the plasma cell tumor-bearing mice. Each tube then receives 50 $\mu$l of S-dil (3% BSA and 10% normal rabbit serum in 0.05 M Tris pH 7.6) containing a constant amount of antiallotype serum (usually an amount previously shown to precipitate about 50% of the labeled antigen in the absence of inhibitor). Control tubes contain labeled antigen and either buffer or antiserum. After incubation for 3 hr at 37°C, chilling to 4°C, and centrifugation at 4°C at 10,000 × *g* for

[1] These tumors have also been successfully passaged at Stanford in (NZB × BALB/cGa)$F_1$.

Downloaded from www.jem.org on May 24, 2005

15 min, 50 μl samples of the supernatant are removed and counted in a well type crystal scintillation counter. The per cent of inhibition is then determined from the following formula:

Per cent inhibition = (1 − I/C) 100 where I = per cent precipitation of labeled antigen in the tube containing labeled antigen, antiserum, and inhibitor; and C = per cent precipitation of labeled antigen in the control tube containing labeled antigen and antiserum.

*Protein Conjugation to Polyaminopolystyrene (PAPS).*—Conjugation of myeloma proteins to PAPS was performed by the diazo coupling method of Webb and LaPresle (27). The weight ratio of PAPS to protein was approximately 10:1, and the reaction was carried out at pH 8.2. Unreacted diazonium groups were blocked with glycine. Absorption of serum was performed by passage through a column of PAPS-protein conjugate.

## RESULTS

*Antigenic Specificities on Normal $\gamma G_{2a}$-Immunoglobulins.*—In this further analysis of the Ig-1 isoantigenic specificities on the class $\gamma G_{2a}$ the same methods of determination and rules for defining specificities have been followed as previously described (6).

In listing the data used to define the presence or absence of each specificity in each of the type strains, the following notation is used: An $I^{125}$-labeled preparation of gamma globulin is indicated with an asterisk following the symbol of the strain from which it was prepared, (for example, C3H*), while normal sera used in inhibition assays are listed by the strain symbols (e.g., C3H). The symbols C3H*-C57BL anti-C3H refer to the use of a labeled C3H gamma globulin preparation with a C57BL anti-C3H antiserum in an inhibition assay. The statement, "(C3H 8)" means C3H has specificity 8. The statement, "(C57BL − 8)" means C57BL does not have specificity 8. Myeloma proteins have occasionally been substituted for preparations of normal gamma globulin, when the myelomas have been found to carry all the isospecificities present on the corresponding class of gamma globulin from normal serum. Thus, in paragraph 5 under $\gamma G_{2a}$-immunoglobulin RPC-5 has been used in place of C3H gamma globulin.

The Ig-1 isoantigenic specificities of $\gamma G_{2a}$ defined by the available antisera for the type strains are listed in Table I.

1. Specificity 8 was previously defined by the failure of SEA (until then undifferentiated from C3H) to completely inhibit C3H*-C57BL anti-C3H precipitation. The type strain distribution was (C3H 8; C57BL −8; A/J 8; SEA −8) (6).

2. A failure of the other type strains to completely inhibit this same reaction cannot however be used to determine whether they have specificity 8 or not, since these strains lack at least one other specificity detected in this reaction. Therefore, the same C57BL anti-C3H antiserum was used with the iodinated gamma globulin of each of the other type strains to see whether that reaction could be completely inhibited by C3H but not by SEA. Such a finding, could only be interpreted as the presence of specificity 8 in the labeled antigen. It was found that the precipitation of DBA* AKR*, and RIII* by C57BL anti-C3H is completely inhibited by both C3H and SEA. CE*-C57BL anti-C3H precipitation is not completely inhibited by SEA. Therefore CE is the only one of these 4 type strains to have specificity 8 (DBA −8; AKR −8; CE 8; RIII −8).

3. NZB anti-NZC precipitates C3H* (NZC has the same allele, $Ig\text{-}1^a$, as C3H;

Downloaded from www.jem.org on May 24, 2005

and NZB has the same allele Ig-1$^e$ as A/J). Therefore C3H has at least one new specificity not previously described (C3H 9; A/J −9).

4. C57BL*-NZB anti-NZC, and CE*-NZB anti-NZC precipitations are both completely inhibited by all type strains except AKR and A/J which do not inhibit. Therefore all 6 of these strains share at least 1 specificity detected by this antiserum, (C57BL 9; DBA 9; AKR −9; CE 9; RIII 9; SEA 9).

5. RPC-5*-NZB anti-NZC precipitation is completely inhibited by C3H and SEA, is not inhibited by AKR or A/J; and is partially inhibited by C57BL, DBA, CE, and RIII. Therefore in addition to detecting 9, this reaction detects a new specificity, 10, (C3H 10; AKR −10; A/J −10; SEA 10).

TABLE I

*Antigenic Specificities Controlled by Ig-1 Alleles on $\gamma G_{2a}$-Immunoglobulins*

| Allele | Type strain* | Antigenic specificities | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| | | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 |
| Ig-1$^a$ | BALB/c‡J | 1§ | 2 | —¶ | — | — | 6 | 7 | 8 | 9 | 10 |
| Ig-1$^b$ | C57BL/10J | — | — | — | 4 | — | — | 7 | — | 9 | — |
| Ig-1$^c$ | DBA/2J | — | 2 | 3 | — | — | — | 7 | — | 9 | — |
| Ig-1$^d$ | AKR/J | 1 | 2 | — | — | 5 | — | 7 | — | — | — |
| Ig-1$^e$ | A/J | 1 | 2 | — | — | 5 | 6 | 7 | 8 | — | — |
| Ig-1$^f$ | CE/J | 1 | 2 | — | — | — | — | — | 8 | 9 | — |
| Ig-1$^g$ | RIII/J | — | 2 | 3 | — | — | — | — | — | 9 | — |
| Ig-1$^h$ | SEA/Gn | 1 | 2 | — | — | — | 6 | 7 | — | 9 | 10 |

* Other strains referred to in this paper carry the following alleles: 129/J, C3H/HeJ, NZC/Bl,-Ig-1$^a$; LP/J,-Ig-1$^b$, NZB,-Ig-1$^e$.

‡ We have changed the Ig-1$^a$ type strain from C3H/HeJ to BALB/cJ because of the availability of BALB/c plasma cell tumors.

¶ Dash indicates specificity is absent.

§ Number indicates specificity is present.

*Antigenic Specificities on Normal $\gamma G_{2b}$-Immunoglobulins.*—Many isoantisera have been tested for their ability to precipitate 2 $I^{125}$-labeled $\gamma G_{2b}$-myelomas. Since no method for separating $\gamma G_{2b}$- from $\gamma G_{2a}$-immunoglobulins of normal mouse serum has so far been found, we are restricted in the analysis of $\gamma G_{2b}$ antigenic specificities to the use of the $\gamma G_{2b}$-myelomas. Hence inhibition assays have been performed with them in the manner described for the $\gamma G_{2a}$-isoantigens, but using $\gamma G_{2b}$-myeloma proteins as labeled antigens. These assays are not inhibited by $\gamma G_{2a}$-myeloma proteins tested. MPC-11 and MPC-31 are BALB/c myelomas, GPC-5 is an NZB myeloma (see later).

We have previously described isoantigens of $\gamma$A-immunoglobulins and termed the responsible locus Ig-2. The isoantigenic locus for $\gamma G_{2b}$-immunoglobulin is therefore called Ig-3. Some of these antigens have also been described by Lieberman et al. (7).

Downloaded from www.jem.org on May 24, 2005

1. MPC-31*-LP anti-129 precipitation is completely inhibited by C3H, DBA, CE, RIII, and SEA, is partially inhibited by AKR and A/J, and is not inhibited by C57BL. This reaction therefore defines a minimum of 2 specificities, (C3H 1, 2; C57BL −1, -2; DBA 1, 2; AKR 1 or 2; A/J 1, −2; CE 1, 2; RIII 1, 2; SEA 1, 2).

2. GPC-5*-BALB/c anti-NZB precipitation is completely inhibited by AKR and A/J and is not inhibited by any other type strains. This reaction therefore defines specificity 3, (C3H −3; C57BL −3; DBA −3; AKR 3; A/J 3; CE −3; RIII −3; SEA −3) (TableII).

*Analysis of Isoantigenic Specificities on Myeloma Proteins GPC-5, GPC-7, and GPC-8.*—Fifty μl samples of serum from GPC-5, GPC-7, and GPC-8

TABLE II

*Antigenic Specificities Controlled by the Ig-3 Locus on $\gamma G_{2b}$-Immunoglobulins*

| Type strain* | Antigenic specificities | | |
|---|---|---|---|
| | 1 | 2 | 3 |
| BALB/cGa | 1 | 2 | — |
| C57BL/10J | — | — | — |
| DBA/2J | 1 | 2 | — |
| AKR/J | 1 or | 2 | 3 |
| A/J | 1 | — | 3 |
| CE/J | 1 | 2 | — |
| RIII/J | 1 | 2 | — |
| SEA/Gn | 1 | 2 | — |

* The strains listed are the type strains for Ig-1.

tumor-bearing mice were separated by electrophoresis as described in methods. The myeloma protein containing fractions were labeled with $I^{125}$, and the precipitability of each of the 3 was determined with several mouse isoantisera (Table III). These results allow some specificities to be assigned and others to be inferred. All specificities not listed were absent; i.e.,

GPC-5: Ig-1.5 and/or Ig-3.3

GPC-7: Ig-1.1,2,?8; Ig-1.6 and/or Ig-1.7; Ig-1.5 and/or Ig-3.3

GPC-8: Ig-1.1,2,?8; Ig-1.6 and/or Ig-1.7; Ig-1.9 and/or Ig-1.10

Several specificities cannot be assigned solely on the basis of precipitation tests. For example, Ig-1.6 and Ig-1.7 are both detected by CE anti-129, which could precipitate GPC-7 and GPC-8 through the presence of either or both of these specificities on the myeloma protein. To distinguish between these possibilities inhibition tests were performed.

1. GPC-7*-CE anti-129 precipitation is completely inhibited by C3H, and only partially by C57BL. This indicates that both Ig-1.6 and Ig-1.7 are on GPC-7, (GPC-7, Ig-1.6,7).

Downloaded from www.jem.org on May 24, 2005

2. GPC-7*-CE anti-129 was completely inhibited with 0.007 $\mu$l of GPC-8 whole serum whereas 0.1 $\mu$l of several NZB $F_1$ hybrid sera was needed to completely inhibit. This indicates that GPC-8 myeloma protein carries specificities Ig-1.6 and Ig-1.7, as these were previously shown to be detected in this assay, (GPC-8, Ig-1.6,7).

3. Both GPC-7*-C57BL anti-C3H and GPC-8*-C57BL anti-C3H precipitations are completely inhibited by C3H but only partially inhibited by SEA. This shows that both myelomas carry Ig-1.8, (GPC-7 and GPC-8, Ig-1.8).

4. GPC-8*-NZB anti-NZC precipitation is completely inhibited by C3H but only partially inhibited by C57BL. This shows that GPC-8 carries both Ig-1.9 and Ig-1.10, (GPC-8, Ig-1.9,10).

TABLE III

*Precipitation of $I^{125}$-Labeled Myeloma Proteins by Various Isoantisera*

| Antiserum | Antigenic specificities detectable by antiserum | | Precipitation of $I^{125}$-labeled myeloma* | | |
|---|---|---|---|---|---|
| | Ig-1 | Ig-3 | GPC-5 | GPC-7 | GPC-8 |
| C57BL anti-C3H | 1, 2, 6, 8 | — | — | + | + |
| C3H anti-DBA/2 | 3 | — | — | — | — |
| C57BL anti-DBA/2 | 2, 3 | — | — | + | + |
| BALB/c anti-C57BL | 4 | — | — | — | — |
| BALB/c anti-NZB | 5 | 3 | + | + | — |
| RIII anti-129 | 1 | — | — | + | + |
| NZB anti-NZC | 9, 10 | — | — | — | + |
| CE anti-129 | 6, 7 | — | — | + | + |
| LP anti-129‡ | — | 1, 2 | — | — | — |

* —, represents less than 2% precipitation; +, represents greater than 50% precipitation (usually between 70% to 90%).

‡ Absorbed with RPC-5 myeloma conjugated to polyaminopolystyrene resin.

The remaining specificities to be assigned are Ig-1.5 and Ig-3.3, which are both defined by the BALB/c anti-NZB serum. The results of inhibition assays using serial dilutions of the myeloma proteins are presented in Fig. 1.

5. GPC-5*-BALB/c anti-NZB precipitation is not completely inhibited by GPC-7. GPC-7*-BALB/c anti-NZB precipitation *is* completely inhibited by similar amounts of either GPC-5 or GPC-7. This indicates that GPC-5 carries Ig-1.5 and Ig-3.3 only one of which is on GPC-7, (GPC-5, Ig-1.5, Ig-3.3).

6. Since GPC-7* is at least 80% precipitable by both BALB/c anti-NZB and RIII anti-129 (anti-Ig-1.1), most (if not all) GPC-7 molecules must carry both Ig-1.1 and the specificity common to GPC-5 and GPC-7. Since Ig-1.1 is a $\gamma G_{2a}$-specificity (carried on the $\gamma G_{2a}$-myelomas 5563 and RPC-5), the common specificity *must be* Ig-1.5. The second specificity detected by BALB/c anti-NZB present only on GPC-5, is Ig-3.3.

The complete list of specificities present on the 3 myelomas is given in Table IV. Consistent with the failure of GPC-7 to completely inhibit GPC-5*-BALB/c anti-NZB precipitation, is the finding that absorption of the BALB/c anti-NZB

Downloaded from www.jem.org on May 24, 2005

serum with GPC-7 myeloma protein bound to PAPS still leaves antibodies which react with approximately 95% of GPC-5*.




FIGS. 1 *a* and 1 *b*. Fig. 1 *a*. Inhibition of precipitation of $I^{125}$-labeled GPC-7 myeloma protein by GPC-5 and GPC-7 myeloma proteins. Antiserum used was BALB/c anti-NZB. Fig. 1 *b*. As for Fig. 1 *a* but using $I^{125}$-labeled GPC-5 myeloma protein.

TABLE IV

*Antigenic Specificities Present on Myelomas Originating in (NZB × BALB/c) $F_1$ Hybrids*

| Myeloma | Ig-1 specificities | | | | | | | | | | Ig-3 specificities | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 1 | 2 | 3 |
| GPC-5 | — | — | — | — | 5 | — | — | — | — | — | — | — | 3 |
| GPC-7 | 1 | 2 | — | — | 5 | 6 | 7 | 8 | — | — | — | — | — |
| GPC-8 | 1 | 2 | — | — | — | 6 | 7 | 8 | 9 | 10 | — | — | — |
| BALB/c normal $\gamma G_2$ | 1 | 2 | — | — | — | 6 | 7 | 8 | 9 | 10 | 1 | 2 | — |
| NZB normal $\gamma G_2$ | 1 | 2 | — | — | 5 | 6 | 7 | 8 | — | — | 1 | — | 3 |

*Analysis of GPC-5 with Rabbit Antisera.*—GPC-5 has previously been typed as a $\gamma G_{2b}$-myeloma (14). Since it carries an Ig-1 and an Ig-3 specificity further investigation of GPC-5 with rabbit antisera was made. A rabbit antiserum was prepared against purified MPC-11 myeloma protein (a $\gamma G_{2b}$-myeloma). This antiserum was then absorbed once with 5563 and once with

Downloaded from www.jem.org on May 24, 2005




FIG. 2. Inhibition of precipitation of $I^{125}$-labeled MPC-31 myeloma protein by various purified myeloma proteins. Each tube contains constant amounts of labeled MPC-31 protein and of rabbit anti-MPC-11 myeloma protein serum absorbed separately with 5563 and RPC-5 proteins bound to PAPS. The amount of myeloma protein used to inhibit is given.

TABLE V

*Inhibition of Precipitation of $I^{125}$-Labeled MPC-31 Myeloma by Normal Sera and Myeloma Proteins*

| Inhibitor | Amount | Inhibition |
|---|---|---|
| | | % |
| BALB/c whole serum | 0.03 μl | 50 |
| NZB " " | 1.00 " | 0 |
| | | |
| MPC-31 myeloma | 0.02 μg | 50 |
| GPC-5 " | 0.02 " | 0 |
| GPC-5 " | 2.00 " | 50 |
| GPC-7 " | 3.20 " | 50 |

Antiserum: Rabbit anti-MPC-11 myeloma absorbed with A/J normal serum conjugated to PAPS.

RPC-5 protein bound to PAPS (both $\gamma G_{2a}$-myelomas) to produce a specific anti-$\gamma G_{2b}$-immunoglobulin antiserum. An inhibition assay was then performed with this antiserum and another $I^{125}$ $\gamma G_{2b}$-myeloma (MPC-31), to avoid any possible detection of an MPC-11 myeloma specific antigen. The results presented in Fig. 2, indicate that this assay is not inhibited by any $\gamma G_{2a}$-myeloma (5563, RPC-5, GPC-7, GPC-8), nor by a $\gamma$A-myeloma (MPC-1). It is com-

Downloaded from www.jem.org on May 24, 2005

pletely inhibited by MPC-31, and is partially inhibited by GPC-5. This partial inhibition confirms that GPC-5 carries $\gamma G_{2b}$-determinants, but also indicates that it lacks some determinant(s) present on MPC-31. A/J and NZB normal serum were also shown to only partially inhibit this reaction.

Another sample of the rabbit anti–MPC-11 serum was absorbed with A/J normal serum bound to PAPS. This absorbed antiserum still precipitates labeled MPC-31 (completeness of absorption shown by its failure to precipitate $I^{125}$-labeled A/J gamma globulin). This reaction was inhibited by BALB/c normal serum but not by A/J or NZB normal sera. This indicates the presence of an antigenic determinant on $\gamma G_{2b}$-immunoglobulins of BALB/c type not present in NZB immunoglobulins. Whereas 0.02 $\mu$g of MPC-31 protein gave a 50% inhibition of this assay, 0.02 $\mu$g of GPC-5 failed to inhibit at all, 100-fold more GPC-5 protein being needed to give the same degree of inhibition (Table V). A 1% contamination of this fraction with normal BALB/c $\gamma G_{2b}$-immunoglobulin would account for the inhibition observed with the GPC-5 fraction. This degree of contamination is expectable since this fraction was isolated from the serum of an (NZB $\times$ BALB/c)$F_1$ mouse carrying GPC-5.

Downloaded from www.jem.org on May 24, 2005

## DISCUSSION

The Ig-1 locus of mice, previously shown to be highly polymorphic with 8 alleles detected in some 70 inbred strains, controls isoantigens (allotypes) on $\gamma G_{2a}$-immunoglobulins. The isoantigens determined by these alleles are comprised of multiple antigenic specificities inherited as a phenogroup. Eight such antigenic specificities had been defined (6). This number has now been increased to 10, and an analysis of the Ig-3 locus, controlling isoantigens on the $\gamma G_{2b}$-immunoglobulins has revealed at least 3 antigenic specificities.

Before discussing the analysis of the myeloma proteins, some explanation for considering the isoantigens on $\gamma G_{2a}$ and $\gamma G_{2b}$ to be controlled by two distinct loci Ig-1 and Ig-3 may be helpful. The explanation is identical with that previously made in designating a distinct locus, Ig-2, for the allotypes (isoantigens) found on $\gamma$A-globulins (5). A gene locus is defined as the length of DNA which codes for a species of polypeptide chain. In each individual mouse there are molecules of 5 immunoglobulin classes $\gamma G_{2a}$, $\gamma G_{2b}$, $\gamma G_1$, $\gamma$A, and $\gamma$M which are distinguished from one another by at least the Fc fragments of their heavy (H) polypeptide chains (15, 16, 28).

These classes all differ for some of the following properties: molecular size, average electrophoretic mobility (15, 16), physiological (29) and metabolic behavior (30), and in antigens (15, 16). The distinction between $\gamma G_{2a}$ and $\gamma G_{2b}$ was originally made only on the basis of antigenic differences. Subsequently a difference in the physiological activities of $\gamma G_{2a}$ and $\gamma G_{2b}$ was found (31). These differences can all be ascribed to the H-chain found in each class.

Recently, mapping of the tryptic peptides of the Fc fragments (and of the entire H-chains) has shown that $\gamma G_{2a}$- and $\gamma G_{2b}$-class distinctions are associated with polypeptide sequence differences. The Fc fragments of all $\gamma G_{2a}$-myeloma proteins tested gave tryptic peptide fingerprints identical to one another. The Fc fragments of all $\gamma G_{2b}$-myeloma proteins tested, also gave fingerprints identical with each other, but, the $\gamma G_{2a}$- and $\gamma G_{2b}$-patterns were distinctly different in the position of some 18 peptides. In addition some 12 peptides of the 2 types of patterns had the same position (32). This is a very welcome support for the immunochemical findings of cross-reactions and differences of the $\gamma G_{2a}$- and $\gamma G_{2b}$-Fc fragments. The $\gamma$A-fingerprints had previously been shown to be distinct (33).

The above is ample reason for concluding that the molecules belonging to each immunoglobulin class, even within one individual mouse, have a common Fc polypeptide which differs from that of other classes. Thus by the definition of locus (above) we must assign different loci to each immunoglobulin class.

Genetic polymorphism has so far been found only for $\gamma G_{2a}$, $\gamma$A, and $\gamma G_{2b}$. The locus designations we have assigned are Ig-1, Ig-2, and Ig-3 respectively. Ig-1 and Ig-2 have been shown to be closely linked genetically as have Ig-1 and Ig-3 (5, 7). Therefore, these loci are clustered in a chromosome region (in the same sense as that used for the H-2 histocompatibility region (34) which may be called the Ig region. Each locus has multiple alleles coding for the H-chains (or Fc fragments) of the respective immunoglobulins. The concept of several linked loci for mouse immunoglobulin classes is an exact parallel of the postulated multiple loci controlling human $\gamma$G-H-chain subgroups. As in the mouse, individual genetic factors (Gm specificities) are each associated with a particular H-chain subgroup (21).

Results of analysis of 3 plasma cell tumors induced by paraffin oil injection into (NZB $\times$ BALB/c)$F_1$ hybrid mice which produce $\gamma G_2$-myeloma proteins have been presented. NZB and BALB/c carry different alleles at both the Ig-1 and Ig-3 loci thus providing the opportunity to analyze the role of each of the 4 alleles present in the hybrids in determining the allotypes of the myeloma proteins. The two tumors GPC-7 and GPC-8 produce $\gamma G_{2a}$-myeloma proteins which will be discussed first. BALB/c and NZB carry respectively Ig-$1^a$ and Ig-$1^e$ alleles. The antigens determined by these alleles have several antigenic specificities in common, i.e. 1, 2, 6, 7, and 8, and each has at least one specificity not present in the other; i.e., BALB/c has 9, 10; and NZB has 5 (Table I). Both GPC-7 and GPC-8 have all the specificities shared by BALB/c and NZB, but GPC-7 has specificity 5 (associated with the Ig-$1^e$ allele), and does not have 9 and 10, while GPC-8 has the specificities 9 and 10 (associated with the Ig-$1^a$ allele), and does not have 5. Thus, each of these two $\gamma G_{2a}$-myeloma proteins is carrying the antigenic specificities determined by only *one or the other* of the parental Ig-1 alleles present in the mouse in which the tumor arose.

Downloaded from www.jem.org on May 24, 2005

Individual myeloma proteins in man of the We and Vi class (21) also called $\gamma_{2b}$ and $\gamma_{2c}$ (35) have (with one exception) (24) been found to have only one of the allelically controlled antigens such as Gma, b, or f (20–22, 24), even when the normal gamma globulin population is carrying several of these antigens. In rabbits heterozygous at the Ab locus (36), and in mice heterozygous at the Ig-1 locus (37), the two allelically controlled isoantigens have been shown to be located on different molecules. It has not however been conclusively eliminated that a small proportion (say 5%), of "heterozygous" molecules also exist, and indeed such molecules can be produced in vitro by hybridization (38). Rabbits heterozygous at the Ab locus have been examined by Pernis et al. (39) who found that the 2 allelic types of protein were always synthesized in different cells. Thus the results with GPC-7 and GPC-8 are in agreement with the general observation that both normal and malignant cells express only one H-chain or L-chain allele (at least at the time of examination).

A further point should be emphasized about these 2 myelomas. In both cases, the protein studied has been isolated from the original host of the tumor. It has been shown that in some mice which have been treated with prolonged injections of adjuvants, and in whom plasma cell tumors arise, separate tumors, i.e. producing different immunoglobulin polypeptide chains, can be found in the one host (40). It might be possible then that in the GPC-7 and GPC-8 lines, there is in fact more than one discrete tumor and that the antigenic specificities are those of several myelomas. This possibility is eliminated by the finding that various unispecific antisera precipitate up to 90% of the myeloma protein (allowing a maximum of 8% contamination by total normal $\gamma G_2$-globulins). These antigenic specificities are hence all on the same molecules.

The third myeloma studied, GPC-5, may be of particular value in understanding at least one aspect of the genetic control of immunoglobulins. This myeloma, which is also derived in a (NZB $\times$ BALB/c)$F_1$ hybrid has the antigenic specificities of only 1 parental strain (NZB). It types unambiguously as $\gamma G_{2b}$- myeloma with 2 rabbit antisera specific for $\gamma G_{2b}$. Results presented in this paper demonstrate that one of these rabbit antisera has antibody activity towards specificities on BALB/c $\gamma G_{2b}$ not present on NZB $\gamma G_{2b}$ and adds further confirmation of GPC-5 being of NZB $\gamma G_{2b}$-type. The only antigenic specificities found on GPC-5 are both defined by the BALB/c anti-NZB serum. This myeloma carries only 1 of the 2 Ig-3 specificities of normal NZB $\gamma G_{2b}$, namely Ig-3.3, but even more remarkable is the finding that it also carries a specificity which is found on normal and myeloma NZB $\gamma G_{2a}$-immunoglobulins, namely Ig-1.5. On the basis of inhibition data for Ig-1.5, and with direct testing by specific antiserum to Ig-3.3, at least 95% of molecules of GPC-5 carry both specificities.

GPC-5 is therefore the first analyzed mouse myeloma protein *not* carrying the entire set of isospecificities normal to its class and genotype, that is, all

Downloaded from www.jem.org on May 24, 2005

$\gamma G_{2a}$- or $\gamma G_{2b}$-molecules previously analyzed do carry all of the antigenic specificities determined by the respective allele present in that individual. GPC-5 is also the first example of a mouse myeloma protein carrying antigenic specificities, and inferentially the amino acid sequences of 2 classes of immunoglobulins.

To account for the occurrence of Ig-1.5 and Ig-3.3, in the same molecules of GPC-5, two basic alternative explanations might be proposed:

1. That this type of molecule, despite lack of prior detection, is a normal $\gamma G_2$-component synthesized by a small proportion of plasma cells prior to tumor induction;

2. That this molecular species did not exist prior to tumor induction. Detailed comments on the specific mechanism of origin of GPC-5 should at present be limited to a consideration of when the recombinational or mutational event occurred. In the case of alternative 1, immediately preceding, this would have been either in the germ line or in somatic cell division of these mice. Alternative 2, immediately preceding, would require that this event was directly related to the actual tumor induction.

These results provide great stimulation to continue the isoantigenic analysis of myeloma proteins, in the expectation that they will throw further light on the genetic control of immunoglobulin structure.


SUMMARY

Further analysis of the isoantigens (allotypes) of 2 classes of normal mouse immunoglobulins, $\gamma G_{2a}$ and $\gamma G_{2b}$, has shown a minimum of 10 specificities for the Ig-1 locus (controlling $\gamma G_{2a}$-antigens) and 3 specificities for the Ig-3 locus (controlling $\gamma G_{2b}$-antigens).

Three $\gamma G_2$-myeloma proteins of plasma cell tumors induced in (NZB $\times$ BALB/c)$F_1$ mice have been analyzed for the isoantigens they carry. NZB mice are genotypically $\underline{\text{Ig-1}^e\ \text{Ig-3}^e}$, while BALB/c are $\underline{\text{Ig-1}^a\ \text{Ig-3}^a}$. Two of the myeloma proteins are $\gamma G_{2a}$-globulins. One of these, GPC-7, carries all the isoantigenic specificities of the Ig-$1^e$ allele while the other, GPC-8, carries all the isoantigenic specificities of the Ig-$1^a$ allele. Thus only one of the parental alleles of the mouse in which the tumor arose is expressed in each of these myeloma proteins.

The third myeloma protein GPC-5, also carries the antigens of only one parental strain (NZB). However GPC-5, a $\gamma G_{2b}$-globulin, carries only one of the Ig-3 specificities normally associated with $\gamma G_{2b}$-globulins of NZB. Most remarkably it also carries one Ig-1 specificity normally associated with $\gamma G_{2a}$-globulins of NZB. This is the first analyzed mouse myeloma shown (*a*) to express some but not all the antigenic specificities normally associated with an allele and (*b*) to carry antigenic specificities controlled by two distinct immunoglobulin loci. The implications of these findings are discussed in relation to the genetic control of immunoglobulins.


Downloaded from www.jem.org on May 24, 2005

We are grateful to Dr. John Fahey for sending us mice carrying several of the established plasma cell tumors in BALB/c mice, and to Mrs. L. A. Herzenberg for a critical review of the manuscript. Excellent technical assistance was provided by Mrs. Susan Sucher and Mr. G. M. Iverson.

## BIBLIOGRAPHY

1. Kelus, A., Moor-Jankowski, J. K., Serum protein antigens of hereditary character, *Protides Biol. Fluids, Proc. Colloq.*, 1961 **9,** 193.
2. Wunderlich, J., and Herzenberg, L. A., Genetics of a gamma globulin isoantigen (allotype) in the mouse, *Proc. Nat. Acad. Sc.*, 1963, **49,** 592.
3. Dubiski, S., and Cinader, B., A new allotypic specificity in the mouse (MuA2), *Canad. J. Biochem. and Physiol.*, 1963, **41,** 1311.
4. Dray, S., Lieberman, R., and Hoffman, H. A., Two murine $\gamma$-globulin allotypic specificities identified by ascitic fluid isoprecipitins and determined by allelic genes, *Proc. Soc. Exp. Biol. and Med.*, 1963, **113,** 509.
5. Herzenberg, L. A., A chromosome region for $\text{gamma}_{2a}$ and $\text{beta}_{2A}$ globulin H chain isoantigens in the mouse, *Cold Spring Harbor Symp. Quant. Biol.*, 1964, **29,** 455.
6. Herzenberg, L. A., Warner, N. L., and Herzenberg, L. A., Immunoglobulin isoantigens (allotypes) in the mouse. I. Genetics and cross-reactions of the $7S\gamma_{2a}$-isoantigens controlled by alleles at the Ig-1 locus, *J. Exp. Med.*, 1965, **121,** 415.
7. Lieberman, R., Dray S., and Potter M., Linkage in control of allotypic specificities on two different $\gamma$G-immunoglobulins, *Science,* 1965, **148,** 640.
8. Herzenberg, L. A., H-2 and immunoglobulin isoantigens (allotypes) in somatic cell genetics, Symposium on Mutational Process, Session IV: Genetic Changes of Somatic Cells, Prague, Academia, 9 through 11 August 1965, in press.
9. Fahey, J. L., Heterogeneity of $\gamma$-globulin, *Advances Immunol.*, 1962, **2,** 42.
10. Fudenberg, H., The hereditary human gamma globulin (Gm) groups. Interpretations and Extensions, *Progr. Allergy*, 1963, **7,** 1.
11. Cohen, S., and Porter, R. R., Structure and biological activity of immunoglobulins, *Advances Immunol.*, 1964, **4,** 287.
12. Potter, M., and Robertson, C. L., Development of plasma cell neoplasms in BALB/c mice after intraperitoneal injection of paraffin-oil adjuvant, heat killed staphylococcus mixtures, *J. Nat. Cancer Inst.*, 1960, **25,** 847.
13. Rask-Nielsen, R., and Ebbesen, P., Reticular neoplasms induced in DBA/2 and CBA mice by intraperitoneal injections of mineral oil, *J. Nat. Cancer Inst.*, 1965, **35,** 83.
14. Goldstein, G., Warner, N. L., and Holmes, M. C., Plasma cell tumor induction in (NZB $\times$ BALB/c)$F_1$ hybrid mice, *J. Nat. Cancer Inst.*, 1966, in press.
15. Fahey, J. L., Wunderlich, J., and Mishell, R., The immunoglobulins of mice. I. Four major classes of immunoglobulins: $7S\gamma_2$-, $7S\gamma_1$-, $\gamma_{1A}(\beta_{2A})$-, and 18S $\gamma_{1M}$-globulin, *J. Exp. Med.*, 1964, **120,** 223.
16. Fahey, J. L., Wunderlich, J., and Mishell, R., The immunoglobulins of mice II. Two subclasses of mouse $7S\gamma_2$-globulins: $\gamma_{2a}$- and $\gamma_{2b}$-globulins, *J. Exp. Med.*, 1964, **120,** 243.
17. Grubb, R., Agglutination of erythrocytes coated with "incomplete" anti-Rh by

Downloaded from www.jem.org on May 24, 2005

certain rheumatoid arthritic sera and some other sera, *Acta Pathol. et Microbiol. Scand.*, 1956, **39**, 195.

18. Ropartz, G., Lenoir, J., and Rivat, L., A new inheritable property of human sera: The InV factor, *Nature*, 1961, **189**, 586.
19. Steinberg, A. G., Progress in the study of genetically determined human gamma globulin types (the Gm and InV groups), *Progr. Med. Genet.*, 1962, **2**, 1.
20. Martensson, L., On the relationships between the $\gamma$-globulin genes of the Gm system, *J. Exp. Med.*, 1964, **120**, 1169.
21. Kunkel, H. G., Allen, J. C., and Grey, H. M., Genetic characters and the polypeptide chains of various types of gamma globulin, *Cold Spring Harbor Symp. Quant. Biol.*, 1964, **29**, 433.
22. Harboe, M., Osterland, C. K., Mannik, M., and Kunkel, H. G., Genetic characters of human $\gamma$-globulins in myeloma proteins, *J. Exp. Med.*, 1962, **116**, 719.
23. Martensson, L., van Loghem, E., Matsumoto, H., and Nielsen, J., Gm(s) and Gm(t): Genetic determinants of human $\gamma$-globulin, *Vox Sanguinis*, 1966, in press.
24. Martensson, L., and Kunkel, H. G., Distribution among the $\gamma$-globulin molecules of different genetically determined antigenic specificities in the Gm system, *J. Exp. Med.*, 1965, **122**, 799.
25. Ceppelini, R., et al., Nomenclature for human immunoglobulins, *Bull. World Health Organ.*, 1964, **30**, 447.
26. Snell, G. D., Hoecker, G., Amos, D. B., and Stimpfling, J. H., A revised nomenclature for the histocompatibility-2 locus of the mouse, *Transplantation*, 1964, **2**, 777.
27. Webb, T., and La Presle, C., Study on the adsorption on and desorption from polystyrene human serum albumin conjugates of rabbit anti-human serum albumin antibodies having different specificities, *J. Exp. Med.*, 1961, **114**, 43.
28. Mishell, R., and Fahey, J. L., Molecular and submolecular localization of two isoantigens (allotypes) of mouse immunoglobulins, *Science*, 1964, **143**, 1440.
29. Nussenzweig, R. S., Merryman, C., and Benacerraf, B., Electrophoretic separation and properties of mouse antihapten antibodies involved in passive cutaneous anaphylaxis and passive hemolysis, *J. Exp. Med.*, 1964, **120**, 315.
30. Fahey, J. L., and Sell, S., The immunoglobulins of mice. V. The metabolic (catabolic) properties of five immunoglobulin classes, *J. Exp. Med.*, 1965 **122**, 41.
31. Ovary, Z., Barth, W. F., and Fahey, J. L., The immunoglobulins of mice. III. Skin sensitizing activity of mouse immunoglobulins, *J. Immunol.* 1965, **94**, 410.
32. Potter, M., *J. Mol Biol.*, 1966, in press.
33. Potter, M., and Kuff, E. L., Disorders in the differentiation of protein secretion in neoplastic plasma cells, *J. Mol. Biol.*, 1964, **9**, 537.
34. Amos, B., Transplantation antigens in mouse, rat and man, *Progr. in Med. Genet.*, 1964, **3**, 106.
35. Terry, W. D., and Fahey, J. L., Subclasses of human $\gamma_2$-globulin based on differences in the heavy polypeptide chains, *Science*, 1964, **146**, 400.
36. Dray, S., Young, G. O., and Nisonoff, A., Distribution of allotypic specificities

Downloaded from www.jem.org on May 24, 2005

among rabbit γ-globulin molecules genetically defined at two loci, *Nature*, 1963, **199,** 52.

37. Warner, N. L., 1965 unpublished observations.
38. Seth, S. K., Nisonoff, A., and Dray, S., Hybrid molecules of rabbit γ-globulin formed by recombination of half molecules of γ-globulins differing in genotype at two loci, *Internat. J. Immunochem.*, 1965, **2,** 39.
39. Pernis, P., Chiappino, G., Kelus, A. S., and Gell, P. G. H. Cellular localization of immunoglobulins with different allotypic specificities in rabbit lymphoid tissues, *J. Exp. Med.*, 1965, **122,** 853.
40. Potter, M., Plasma cell neoplasma in a single host: A mosaic of different protein producing cell types, *J. Exp. Med.*, 1962, **115,** 339.

Downloaded from www.jem.org on May 24, 2005